POST-APPROVAL SAFETY STUDY (PASS) OF THE UTILIZATION PATTERN OF APIXABAN IN SWEDEN

First published: 19/11/2013

Last updated: 13/03/2024





Administrative details

EU PAS number	
EUPAS5177	
Study ID	
14474	
DARWIN EU® study	
No	
Study countries	
Sweden	

Study description

This will be a descriptive study using retrospectively collected data from electronic health recorddatabases. The study will describe the utilization pattern of apixaban in Sweden (01 Jan 2012 through 31 Dec 2014).

Study status

Finalised

Research institutions and networks

Institutions



Contact details

Study institution contact

Stephen Schachterle stephen.schachterle@pfizer.com

Study contact

stephen.schachterle@pfizer.com

Primary lead investigator

Stephen Schachterle

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 16/09/2011

Actual: 16/09/2011

Study start date

Planned: 01/10/2014 Actual: 05/11/2014

Date of final study report

Planned: 31/05/2016

Actual: 20/05/2016

Sources of funding

• Pharmaceutical company and other private sector

More details on funding

Bristol-Myers Squibb, Pfizer

Study protocol

cv185103st-prot (pfizer-protocol-b0661017).pdf (127.33 KB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Data collection methods:

Secondary use of data

Main study objective:

The overall objective of this study is to describe the utilization patterns of apixaban in Sweden.

Study drug and medical condition

Medicinal product name

ELIQUIS

Population studied

Short description of the study population

Patients identified in the database who have received an apixaban dispensation during the study period 01 Jan 2012 through 31 Dec 2014.

Age groups

- Adolescents (12 to < 18 years)
- Children (2 to < 12 years)
- Infants and toddlers (28 days 23 months)
- Preterm newborn infants (0 27 days)
- Term newborn infants (0 27 days)
- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Estimated number of subjects

Study design details

Outcomes

Off label use of apixaban.

Data analysis plan

Descriptive analyses of the data will be conducted. The proportion patients receiving the drug for indications within and outside the approved label in each of the study years will be estimated and any trend over time will be described.

Documents

Study results

study-cv185103st-csr-final-red.pdf (1.09 MB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s), other Swedish National Healthcare Registries Sweden		
Data sources (types)		
Other		
Data sources (types), other		
Swedish National Healthcare Registries		
Use of a Common Data Model (CDM)		
CDM mapping		
No		
Data quality specifications		
Check conformance		
Unknown		

Check stability

Unknown

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No